After 2 randomized clinical trials found it as safe and effective as the standard 3-drug regimen, the FDA approved the first 2-drug regimen for adults with HIV-1 who have never been treated with ART.
While neurocognition can increasingly decline with age among individuals with HIV, researchers of a study presented at CROI 2019 determined which factors are connected with neurocognitive decline in the...
As effective HIV interventions have been identified, the design and interpretation of HIV prevention trials has evolved. David Dunn, from University College London, explained these changes during CROI...
Researchers designed a survey to determine whether pregnant women with HIV knew their partner’s HIV status, their prevention or treatment plan, and if they had health insurance.
In this study, the researchers examined adipose tissue changes of men with HIV who were taking cART to determine whether diagnosing metabolic syndrome rather than lipodystrophy is better for cardiometabolic...
In a new study, researchers examined whether HIV is independently associated with abdominal obesity, elevated LDL-C, hypertriglyceridemia, and hypertension.